Eisai Expands Oncology Pipeline With SymBio Lymphoma Treatment
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai has signed a licensing agreement with Japanese start-up SymBio Pharmaceuticals to jointly develop and commercialize lymphoma treatment bendamustine (SyB L-0501) in Japan
You may also be interested in...
India Seeks Partners To Set Up Generic Drug Store Chain In Every District
NEW DELHI - India's government is seeking applications from pharmaceutical companies, non-governmental organizations and other groups as partners for a push to open a chain of low-cost generic drug stores
India Seeks Partners To Set Up Generic Drug Store Chain In Every District
NEW DELHI - India's government is seeking applications from pharmaceutical companies, non-governmental organizations and other groups as partners for a push to open a chain of low-cost generic drug stores
Eisai’s Ontak sBLA Granted U.S. FDA Approval
TOKYO - U.S. FDA granted full approval to Eisai's biologic Ontak (denileukin) for intravenous injection for treating a recurrent type of lymph node cancer, cutaneous T-cell lymphoma in patients whose malignant cells express the CD25 component of the interleukin-2 receptor